estrogens

Can interfere with suppression and compromise diagnostic tests, such as the dexamethasone suppression test.

Consider this interaction when interpreting diagnostic tests for Cushing syndrome, as increased CBG can lead to misleadingly normal or suppressed test results.

Source: G&G 14e · p1016

Women taking oral, but not transdermal, estrogen may require larger GH doses to achieve the target IGF-1 level.

A larger dose of somatropin is needed to maintain the same IGF-1 level.

Source: G&G 14e · p930

Reduced glucose-lowering effect of sulfonylureas.

Source: G&G 14e · p1034

Reduced efficacy of ursodeoxycholic acid in dissolving gallstones.

Avoid concomitant use if ursodeoxycholic acid is used for gallstone dissolution. If used for other indications, monitor for reduced efficacy.

Pharmacologic antagonism; estrogens counteract letrozole effect

Avoid concurrent use

Source: Kimi deep-research + Cla

Combined estrogen-progestin therapy increases risk of thromboembolic events, stroke, and breast cancer compared to estrogen alone. Progesterone protects endometrium but adds thrombotic risk.

Use lowest effective dose for shortest duration. Screen for thromboembolic risk factors. Discontinue if thrombotic event occurs. Annual risk-benefit assessment.

Source: Kimi deep-research + Cla